$PFSA

HRT FINANCIAL LP purchased $873 of PFSA

HRT FINANCIAL LP purchased 926 shares of Profusa, Inc. (PFSA) at $0.94 on 2026-08-06.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 10, 2026, 7:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 7:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Neutral
low confidence
Mentioned
$PFSA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The filing adds incremental ownership information (post-transaction holdings) but does not provide new guidance, trial results, contracts, or regulatory developments.

02

Market read

Traders may treat the disclosure as a minor sentiment datapoint, but it is not a standalone fundamental catalyst.

03

What to watch

Because the filing is a small-dollar open-market buy and lacks a 10b5-1 plan, traders should avoid extrapolating it into a durable demand signal without corroborating news.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10, transaction dated 2026-08-06

Background

This is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA) by HRT Financial LP, identified as a 10% owner.

Company-level read

Ticker impact

$PFSANeutralLow confidence
Context

Profusa, Inc. disclosed via Form 4 that HRT Financial LP bought 926 shares of PFSA on 2026-08-06 at $0.9430/share.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider ownership activity.

Evidence & confidence

The transaction size is small ($873) and is not accompanied by new operational, financial, or regulatory information in the filing.

Market effects

No sector read-through; this is a routine insider/owner transaction with no disclosed business catalyst.

None indicated.

None indicated.

Counterpoint

The purchase may reflect administrative rebalancing or liquidity needs rather than a bullish view on Profusa’s prospects.

Key entities

  • Profusa, Inc.

    Company subject of the Form 4 disclosure, ticker PFSA.

  • HRT Financial LP

    Reporter of the Form 4 transaction, bought 926 shares on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.